The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).
Thomas Powles
Consultant or Advisory Role - Genentech; GlaxoSmithKline
Nicholas J. Vogelzang
Employment or Leadership Position - US Oncology
Consultant or Advisory Role - Celgene
Honoraria - Pfizer
Research Funding - Novartis
Gregg Daniel Fine
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Joseph Paul Eder
No relevant relationships to disclose
Fadi S. Braiteh
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Roche
Yohann Loriot
No relevant relationships to disclose
Cristina Cruz Zambrano
No relevant relationships to disclose
Joaquim Bellmunt
Consultant or Advisory Role - Genentech (U)
Howard A. Burris
No relevant relationships to disclose
Siew-leng Melinda Teng
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche/Genentech
Xiaodong Shen
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche/Genentech
Hartmut Koeppen
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche/Genentech
Priti S. Hegde
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche/Genentech
Daniel S. Chen
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche/Genentech
Daniel Peter Petrylak
Honoraria - Genentech